The suppression of malaria with dapolar: a trial of 4-monthly doses in a village community in the Gambia, West Africa.
D000083:Acetanilides / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000655:Amodiaquine / Q000008:administration & dosage; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005714:Gambia; D006400:Hematocrit; D006452:Hemoglobinometry; D006801:Humans; D007114:Immunization / Q000009:adverse effects; D007223:Infant; D008288:Malaria / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D010961:Plasmodium / Q000302:isolation & purification; D010963:Plasmodium falciparum / Q000302:isolation & purification; D010965:Plasmodium malariae / Q000302:isolation & purification; D011247:Pregnancy; D013450:Sulfones / Q000008:administration & dosage; D014227:Triazines / Q000008:administration & dosage
D000083:Acetanilides; D000962:Antimalarials; D013450:Sulfones; D014227:Triazines; D000655:Amodiaquine